20 Jul Laverock Therapeutics

Posted at 14:42h in by Brittany Miller

David Venables, Ph.D., CEO

Oct. 12 | 11:00am | Rentschler ATMP Ballroom

Stevenage, Herefordshire, UK

(Private)

Laverock Therapeutics is developing the next generation of programmable allogeneic cell therapies though our novel miRNA platform (GEiGS). Gene Editing induced Gene Silencing (GEiGS) utilizes the cells’ own endogenous miRNA expression profiles and redirects them to knock down target genes of choice, generating silencing in a stable, consistent, tunable and programmable manner in response to the stage of cell development, activation, or its’ in vivo disease related environment.

www.laverocktx.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 7-9, 2024
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions